What is SeqLL?
SeqLL Inc. is a development-stage life sciences company focused on creating scientific assets and novel intellectual property within multiple "omics" fields. The company's core innovation lies in its True Single Molecule Sequencing ("tSMS®") technology, which aims to empower researchers and clinicians. By accelerating the understanding of disease mechanisms and fundamental biological processes, SeqLL intends to contribute to major advancements in scientific research and development.
How much funding has SeqLL raised?
SeqLL has raised a total of $1.1M across 2 funding rounds:
Series A
$1M
Debt
$150K
Series A (2014): $1M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Key Investors in SeqLL
PPP
Public-Private Partnership
What's next for SeqLL?
With a recent major strategic investment and substantial total funding, SeqLL is positioned for significant growth and technological advancement. The company's focus on "omics" and its unique tSMS® technology suggest a trajectory towards scaling its research services and instrumentation offerings. This capital infusion is likely to fuel further development of its platform, expand its research collaborations, and potentially move towards commercialization, solidifying its role in accelerating scientific discovery in life sciences.
See full SeqLL company page
